Stone X Group Inc. Abb Vie Inc. Transaction History

Stone X Group Inc.

$1.14 Billion
Q3 2024

A detailed history of Stone X Group Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Stone X Group Inc. holds 32,720 shares of ABBV stock, worth $5.79 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares

32,720

Previous 30,582 6.99%

Holding current value

$5.79 Million

Previous $5.25 Million 23.2%

% of portfolio

0.57%

Previous 0.51%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$163.84 - $199.33 $350,289 - $426,167	2,138 Added 6.99%	32,720 $6.46 Million
Q2 2024 Aug 07, 2024	BUY	$154.79 - $180.76 $384,498 - $449,007	2,484 Added 8.84%	30,582 $5.25 Million
Q1 2024 May 01, 2024	BUY	$159.82 - $182.1 $601,242 - $685,060	3,762 Added 15.46%	28,098 $5.12 Million
Q4 2023 Feb 12, 2024	BUY	$137.6 - $154.97 $204,886 - $230,750	1,489 Added 6.52%	24,336 $3.77 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $24,580 - $28,455	-184 Reduced 0.8%	22,847 $3.41 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $303,580 - $377,785	-2,291 Reduced 9.05%	23,031 $3.1 Million
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $551,108 - $634,683	3,811 Added 17.72%	25,322 $4.04 Million
Q4 2022 Feb 10, 2023	BUY	$138.31 - $165.87 $76,208 - $91,394	551 Added 2.63%	21,511 $3.48 Million
Q3 2022 Nov 08, 2022	BUY	$134.21 - $153.93 $207,757 - $238,283	1,548 Added 7.97%	20,960 $2.81 Million
Q2 2022 Jul 27, 2022	BUY	$137.62 - $174.96 $2.67 Million - $3.4 Million	19,412 New	19,412 $2.97 Million
Q1 2022 May 11, 2022	SELL	$131.98 - $163.75 $2.93 Million - $3.64 Million	-22,213 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $418,332 - $529,311	3,894 Added 21.26%	22,213 $3.01 Million
Q3 2021 Oct 20, 2021	SELL	$106.4 - $120.78 $5,532 - $6,280	-52 Reduced 0.28%	18,319 $1.98 Million
Q2 2021 Aug 06, 2021	BUY	$105.21 - $117.21 $149,608 - $166,672	1,422 Added 8.39%	18,371 $2.07 Million
Q1 2021 Jun 23, 2021	BUY	$102.3 - $112.62 $96,980 - $106,763	948 Added 5.92%	16,949 $1.83 Million
Q4 2020 Feb 03, 2021	BUY	$80.49 - $108.67 $59,643 - $80,524	741 Added 4.86%	16,001 $1.71 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $128,263 - $150,539	1,493 Added 10.84%	15,260 $1.34 Million
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $98,535 - $131,855	1,343 Added 10.81%	13,767 $1.35 Million
Q1 2020 Apr 30, 2020	BUY	$64.5 - $97.79 $1,290 - $1,955	20 Added 0.16%	12,424 $946,000
Q4 2019 Jan 24, 2020	BUY	$72.13 - $90.25 $128,463 - $160,735	1,781 Added 16.77%	12,404 $1.1 Million
Q3 2019 Nov 12, 2019	BUY	$62.98 - $75.72 $34,450 - $41,418	547 Added 5.43%	10,623 $804,000
Q2 2019 Jul 17, 2019	BUY	$65.7 - $83.98 $661,336 - $845,342	10,066 Added 100660.0%	10,076 $733,000
Q2 2019 Jul 12, 2019	SELL	$65.7 - $83.98 $547,018 - $699,217	-8,326 Reduced 99.88%	10 $0
Q1 2019 Apr 05, 2019	BUY	$77.14 - $90.79 $91,179 - $107,313	1,182 Added 16.52%	8,336 $0
Q4 2018 Jan 15, 2019	SELL	$77.85 - $96.01 $11,911 - $14,689	-153 Reduced 2.09%	7,154 $659,000
Q3 2018 Oct 03, 2018	BUY	$88.91 - $98.84 $29,251 - $32,518	329 Added 4.71%	7,307 $0
Q2 2018 Jul 23, 2018	SELL	$89.78 - $106.23 $16,968 - $20,077	-189 Reduced 2.64%	6,978 $646,000
Q1 2018 Apr 19, 2018	SELL	$92.01 - $123.21 $155,588 - $208,348	-1,691 Reduced 19.09%	7,167 $0
Q4 2017 Feb 09, 2018	BUY	$89.56 - $98.21 $44,153 - $48,417	493 Added 5.89%	8,858 $857,000
Q3 2017 Nov 13, 2017	SELL	$69.85 - $89.22 $1.54 Million - $1.97 Million	-22,065 Reduced 72.51%	8,365 $0
Q2 2017 Aug 31, 2017	BUY	N/A	30,430	30,430 $2.21 Million

Others Institutions Holding ABBV

# of Institutions

3,848

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Account